The incidence of side effects is classified according to the recommendations of the World Health Organization: very often - at least 10%; often - not less than 1%, but less than 10%; infrequently - not less than 0.1%, but less than 1%, rarely - not less than 0.01%, but less than 0.1%; very rarely - 0.01%, including isolated cases.
From the nervous system: very often - headache, insomnia; often - dizziness, carpal tunnel syndrome, anorexia, depression; infrequently - drowsiness.
From the cardiovascular system: very often - the "tides" of blood to the face.
On the part of the digestive system: very often - nausea; often - vomiting, abdominal pain, constipation, indigestion, diarrhea.
From the skin and subcutaneous tissues: very often - increased sweating; often - skin rash, alopecia.
From the musculoskeletal system: very often - joint and skeletal muscle pain, stiffness of the joints; often - osteoporosis, fractures.
Other: very often - increased fatigue; often - pain of unspecified localization, peripheral edema; infrequently, asthenia.
Approximately 20% of patients (especially in patients with initial lymphopenia) experienced a periodic decrease in the number of lymphocytes. However, the average number of lymphocytes in these patients did not change significantly with time, and a concomitant increase in the incidence of viral infections was not observed.
Sometimes there was an increase in the activity of "hepatic enzymes" and alkaline phosphatase (APF),mainly in patients with liver and bone metastases, as well as in the presence of other liver lesions (it is not established whether these changes are related to the use of exemestane or not).
According to post-marketing research, adverse reactions from the hepatobiliary system, such as hepatitis (including cholestatic), were noted.